China’s moment is now: perspectives on the inexorable rise of Chinese biopharma innovation

International understanding of China’s arrival as a leading player on the world stage as an innovator of new medicines is now ubiquitous.

This applies whether the context is a US Congress report on the extent of Chinese API control and its growing scientific prowess as a potential threat to the USA, or a western pharma boardroom or investor meeting where potential partnerships with or investments into impressive, fast-moving China-based companies are being discussed.

A perspective from the inside was provided by three speakers at a China-focused panel at this month’s Financial Times’ Global Pharma and Biotech Summit in London, UK.